Efficacy of Olaparib (ola) Plus Abiraterone (abi) Vs Placebo (pbo) Plus Abi in the Non-Brca Mutation (non-Brcam) Subgroup of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcprc) in the Propel Trial
Loading...
Date
2023-10
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Open Access Color
Green Open Access
No
OpenAIRE Downloads
OpenAIRE Views
Publicly Funded
No
BIP! Indicators
Impulse
Average
Influence
Average
Popularity
Average
Abstract
[No abstract available]
Description
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN
ORCID
Keywords
Fields of Science
Citation
WoS Q
Q1
Scopus Q
Q1
OpenCitations Citation Count
N/A
Source
Annals of Oncology
Volume
34
Issue
Start Page
S975
End Page
S976
PlumX Metrics
Citations
CrossRef : 1
Captures
Mendeley Readers : 8
Web of Science™ Citations
1
checked on May 02, 2026
Page Views
1
checked on May 02, 2026
Google Scholar™
